Search

Displaying results 1601 - 1610 of 4344 in total
  1. Drug

    Chondroitin sulfate

    go.drugbank.com/drugs/DB09301
    ApprovedInvestigationalNutraceutical

    Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA). The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, a...

  2. Drug

    Technetium Tc-99m sulfur colloid

    go.drugbank.com/drugs/DB09397
    Approved

    This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray. … intended usage, Technetium 99m sulfur colloid enters the capillaries and is transported to the lymph nodes (subcutaneous injection), mixes with peritoneal fluid (intraperitoneal injection), is taken up by

  3. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. … It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell

  4. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. … [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]

  5. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

  6. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [A249070] It is a taurine conjugate of [ursodeoxycholic acid] [A249065] with comparable therapeutic efficacy and safety,[A249070] but a much higher hydrophilicity.

  7. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin

    Products: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
  8. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis. … [L51109] Soft drugs are designed to reduce systemic toxicity while enhancing local efficacy by employing retrometabolic drug design, in which a molecule contains a metabolically sensitive moiety that promotes

  9. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab is produced by a recombinant cell line cultured by continuous perfusion. … In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.

  10. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.